Since 1–3% of all endometrial cancers are connected to Lynch syndrome, it has been suggested that universal screening by immunohistochemical staining for the four most common altered genes (MLH1, MLH2, MSH6, or PMS2) is a method for identifying previously unknown hereditary cases and therefore provides an opportunity for appropriate counseling to the patients and their families [22]. This evidence concerns the gene PMS2 and Lynch syndrome.